Dec 212023

Forthcoming HHS Regulatory Actions and Opportunities Relevant for Pharmaceutical Manufacturers for the Rest of this Year and Next

Meenakshi Datta and Catherine Y. Starks
, , , ,

Pharmaceutical manufacturers need to note some key forthcoming regulatory actions and opportunities which the Department of Health and Human Services (“HHS”) has recently published. Meena Datta and Catherine Starks give a bird’s eye view of the key points, the key dates and the stage which each new rule has reached.

Earlier this month, the Office of Information and Regulatory Affairs (OIRA) released its annual Fall 2023 Unified Agenda of Regulatory and Deregulatory Agenda (the “Agenda”). The Agenda details actions that Federal administrative agencies “plan to issue in the near and long term,” including several by the Department of Health and Human Services (“HHS”) which are relevant to pharmaceutical manufacturers. Below we include high-level summaries of certain of those HHS actions, organized by anticipated publication date.  In short, two major drug pricing rules are anticipated – one yet this year – along with a potential proposal for new Federal Anti-Kickback Statute (“AKS”) safe harbors, and a potential proposal to make certain revisions to the exclusion authority of HHS, Office of Inspector General (“OIG”).  More detailed Sidley Updates will follow if and as these anticipated regulatory actions unfold.  We look forward to supporting your efforts with identifying pitfalls and opportunities with these likely actions as we head into 2024.

According to the Agenda abstract, the key items, in order of anticipated publication date, are:

Agency Title Stage of Rulemaking Summary Anticipated Publication Date
 

HRSA

  

340B Drug Pricing Program; Administrative Dispute Resolution

  

Final Rule

  

This final rule will revise the Administrative Dispute Resolution final rule currently in effect (which we discussed in a Sidley Update) and will apply to all drug manufacturers and covered entities that participate in the 340B Drug Pricing Program.

The Office of Management and Budget (“OMB”) received this final rule for review on October 16, 2023.

 

  

December 2023
 

OIG

  

Health Care Programs: Fraud and Abuse; Revisions to the Office of Inspector General’s Exclusion Authorities

  

Proposed Rule

  

This proposed rule addresses exclusion authorities of the OIG and seeks to, among other things:

  • Authorize exclusion of manufacturers that misclassify outpatient drugs, fail to correct such misclassifications, or provide false information or data related to drug pricing or product information;
  • Modify or eliminate various aggravating and mitigating factors used to set the length of an exclusion; and
  • Modify public notice requirements.

The OMB has not yet received this proposed rule for review.

 

  

May 2024
 

CMS

  

Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program

  

Final Rule

  

This rule “finalizes requirements related to manufacturers’ misclassification of covered outpatient drug products under the Medicaid Drug Rebate Program (MDRP)…beneficiary protections, [and] MDRP program integrity and administration changes.”

The related Proposed Rule (discussed in a Sidley Update) was released in May 2023 and also addressed the following proposals:

  • Revising the CMS’s prior guidance and requiring manufacturers to “stack” cumulative price concessions provided to different entities when determining Best Price;
  • Revising the CMS’s definition of “manufacturer” for purposes of the National Drug Rebate Agreement (“NDRA”) to purportedly “clarify” that all labelers associated or affiliated with a manufacturer must have an NDRA in effect in order to satisfy the statutory requirement for the manufacturer to have an NDRA in effect;
  • Defining “market date” for purposes of Average Manufacturer Price calculations as “the date on which the [covered outpatient drug] was first sold by any manufacturer.”

OMB has not yet received this final rule for review.

 

  

June 2024
 

OIG

  

Medicare and State Health Care Programs: Fraud and Abuse; Establishment of New Safe Harbors Under the Federal Anti-Kickback Statute

  

Proposed Rule

  

This proposed rule would propose safe harbors under the AKS to protect:

  • Certain bona fide mental health and behavioral health improvement or maintenance programs provided by hospitals, ambulatory surgical centers, community health centers, rural emergency hospitals, skilled nursing facilities, or similar entities, as determined by the Secretary, to physicians or other clinicians;
  • Certain evidence-based contingency management programs for the treatment of substance use disorders.

OMB has not yet received this proposed rule for review.

 

  

August 2024

This post is as of the posting date stated above. Sidley Austin LLP assumes no duty to update this post or post about any subsequent developments having a bearing on this post.

Meenakshi Datta

Chicago

mdatta@sidley.com

Catherine Y. Starks

Chicago

cstarks@sidley.com

You might also like
New Guidance on Parallel Import Licensing Applicable to Northern Ireland Under the Windsor Framework

Brexit brought new challenges to the pharmaceutical industry, one of them being the special situation of Northern Ireland (NI), which, although part of the UK, remained subject to EU law under the NI Protocol. Pharmaceutical products placed on the NI market had to comply with EU law. For import purposes this created de facto an EU border between NI and the rest of the UK (namely England, Wales, and Scotland). The Windsor Framework provides a new set of arrangements to restore the smooth flow of trade within the UK.

EU’s Overhaul Of Pharma Legislation Amended With Uneasy IP Compromises

On March 19, 2024, a set of 100 “Compromise Amendments” to the European Commission’s far-reaching overhaul of the EU’s rules for medicines, the Pharmaceutical Review (the Review), was adopted by the European Parliament’s ENVI Committee. Maarten Meulenbelt, Chris Boyle and Zina Chatzidimitriadou explain the main changes, associated risks, and next steps.

Points To Check When Selling Food Supplements Outside The U.S.

Major U.S. companies are expanding their vitamins, minerals, and botanicals businesses into Europe. Diane McEnroe, Anna-Shari Melin, and Nadja Schwarz explain what to consider in relation to formulation, labelling, and marketing language when targeting this market.